BC Innovations | Jul 10, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Purinergic receptor P2Y G protein-coupled 2 (P2RY2; P2Y2) Cell culture and mouse studies suggest antagonizing P2Y2 could be useful for treating liver cancer....
BC Innovations | Aug 1, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Purinergic receptor P2Y G protein-coupled 2 (P2RY2; P2Y2) In vitro and mouse studies suggest antagonizing the adenine nucleotide receptor P2Y2...
BC Innovations | May 17, 2012
Targets & Mechanisms

Paradoxical P2X7

Italian researchers have shown in vivo that inhibiting the P2X7 receptor, rather than agonizing it as previously thought, can treat cancer. 1 The findings could open up a new disease area for companies developing P2X7...
BC Innovations | Sep 15, 2011
Cover Story

New targets for HIV

The mechanisms by which HIV binds to and fuses with host cells are well documented, but the pathway mediating the intermediate steps between binding and fusion is murky. Now, researchers in France and Italy have...
BC Innovations | Sep 8, 2011
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS Pannexin 1 (PANX1); purinergic receptor P2Y G protein-coupled 2 (P2RY2; P2Y2); protein tyrosine kinase 2b (PTK2B; PYK2) Cell culture studies suggest inhibiting purinergic...
BC Week In Review | Feb 21, 2011
Company News

Inspire ophthalmic news

Inspire will reduce headcount by 65 (27%) to 175 and will discontinue its pulmonary program, including cystic fibrosis candidate denufosol to focus on its eye care business. In January, the second-generation P2Y2 receptor agonist missed...
BC Extra | Feb 18, 2011
Company News

Inspire cutting 27%, dropping denufosol

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) will reduce its headcount by 65 (27%) and discontinue its pulmonary program, including cystic fibrosis (CF) candidate denufosol. In January , the second-generation P2Y2 receptor agonist missed the primary endpoint in the...
BC Week In Review | Jan 10, 2011
Clinical News

Denufosol tetrasodium: Phase III data

In the double-blind, international Phase III TIGER-2 trial in 466 CF patients, denufosol missed the primary endpoint of significantly improving FEV1 at 48 weeks vs. placebo (40 vs. 32 mL, p=0.742). Denufosol also missed the...
BioCentury | Jan 10, 2011
Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 1/7cls Acorda Therapeutics Inc. (NASDAQ:ACOR) Leerink Joshua Schimmer Upgrade Market outperform (from market perform) 2% $27.67 Schimmer upgraded based on his monthly patient modeling...
BC Extra | Jan 4, 2011
Top Story

Inspire misses CF endpoint

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) fell $4.93 (59%) to $3.47 on Monday after denufosol missed the primary endpoint in the Phase III TIGER-2 trial to treat cystic fibrosis. The second-generation P2Y2 receptor agonist did not significantly...
Items per page:
1 - 10 of 162